PHARMACY

Liraglutide more effective than exenatide in Type 2 diabetes treatment

BY Alaric DeArment

MONTREAL New data from a phase 3 trial show that the drug liraglutide is more effective than exenatide in the treatment of Type 2 diabetes.

Liraglutide is Novo Nordisk’s investigative diabetes drug; exenatide is the generic name of Eli Lilly’s Byetta.

The results, presented Friday to the Canadian Diabetes Association and the Canadian Society of Endocrinology, found that once-daily liraglutide was more effective at improving blood-glucose control than twice-daily exenatide.

The study included 464 people with Type 2 diabetes who received 1.8 mg of liraglutide once daily or 10 micrograms of exenatide twice daily, both as an add-on to their existing treatment comprising metformin or sulphonylurea, over a period of 26 weeks. Patients receiving liraglutide experienced significantly less hypoglycemia compared to those using exenatide.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

GlaxoSmithKlines acquires Bristol-Myers Squibb’s Egyptian mature products business

BY Alaric DeArment

LONDON GlaxoSmithKline has acquired the Egyptian mature products business of Bristol-Myers Squibb, the British drug maker announced Wednesday.

GSK said the acquisition, worth $210 million, is a move to accelerate sales growth and further extend its pharmaceutical portfolio in emerging markets.

“This acquisition is an important step forward in GSK’s strategy to accelerate sales growth in emerging markets,” GSK president for emerging markets Abbas Hussain said in a statement. “It will enable us to build and diversify our existing branded pharmaceuticals portfolio and signals our strong commitment to provide quality medicines to patients in Egypt and other countries in the Middle East and North Africa regions.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

‘Face the Nation’ anchor Schieffer to headline NACDS Foundation event

BY Jim Frederick

ALEXANDRIA, Va. The National Association of Chain Drug Stores Foundation revealed today that the keynote speaker at the 2008 annual NACDS Foundation Dinner will be Bob Schieffer, anchor of the CBS News’ Sunday public affairs broadcast “Face the Nation.” Schieffer, who also serves as CBS News chief Washington correspondent, will address attendees Dec. 2 at the Sheraton New York Hotel and Towers in New York City.

NACDS’ announcement is a timely one. Schieffer, one of the few broadcast or print journalists to have covered all four major beats in the nation’s capital—the White House, the Pentagon, the State Department and Capitol Hill, moderated the third and final Presidential debate this week.

“Bob Schieffer demonstrated as moderator of this week’s presidential debate that he asks the questions on the minds of Americans relating to political and national affairs in each of his broadcasts,” said Phil Schneider, NACDS Foundation president. “His conversational style enables him to delve into his stories and share a comprehensive look at the issues facing the country.  The NACDS Foundation is delighted to have Mr. Schieffer as the keynote speaker at the 10th annual Foundation dinner this year.”

For more information or to register for the Foundation dinner, please visit www.nacdsfoundation.org.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?